Previous [39] and more recent (Figure 1A) findings by our lab implicated changes in ion channel expression and Ca2+ signaling as a mechanism of adaptation and drug tolerance to BRAFi in BRAF-mutant melanoma. The gene discussed is BRAF; the disease is melanoma.